752
Views
48
CrossRef citations to date
0
Altmetric
Brief Report

Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis

, , , &
Pages 1425-1429 | Accepted 19 Apr 2011, Published online: 23 May 2011
 

Abstract

Objectives:

Chronic obstructive pulmonary disease (COPD) is an irreversible and often progressive disease that requires lifelong adherence to complicated drug therapy regimens. The well established Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend specific drug therapy protocols, yet patient adherence to drug therapy and physician adherence to prescribing guidelines is reported to be suboptimal. In this claims based analysis of COPD patients, drug therapy treatment patterns including inhaled corticosteroids and long acting bronchodilator use were evaluated by COPD severity level.

Methods:

A cohort of patients with COPD (without co-existing asthma) was identified in Thomas Reuters MarketScan Commercial Database 2007 (diagnosis codes 491.xx, 492.xx, 496.xx). Using one year (2007) of claims data, a COPD severity risk score was calculated for each patient using established claim logic. Severity levels of mild, moderate, severe, and very severe were established to mimic the GOLD severity levels. Each patient's claim experience was examined for inhaled corticosteroid and long acting bronchodilator use for compliance with GOLD guidelines.

Results:

Prevalence of COPD (without co-existing asthma) was 0.7% (44,366 cases). The distribution of COPD subjects into claim based severity levels was 30% mild, 53% moderate, 14% severe and 3% very severe. Claims for inhaled corticosteroid therapy were identified for 8% of mild and 19% of moderate COPD patients; claims for short acting bronchodilator therapy without concomitant use of long acting bronchodilators were identified for 20% of moderate, 14% of severe and 8% of very severe COPD patients; and claims for single long acting bronchodilator therapy in combination with inhaled corticosteroid therapy were identified for 12% of moderate, 19% of severe and 2% of very severe COPD patients.

Conclusions:

This analysis suggests less than optimal compliance with recommended drug therapy treatment for COPD patients based on GOLD guidelines. This study further suggests the utility of claims data analyses for providing reasonable aggregate distributions of COPD severity which allows for health plans and disease management programs to stratify COPD patients by severity level and examine opportunities for improved drug therapy management. Study findings should be considered in the context of the study limitations.

Transparency

Declaration of funding

This study was funded by Novartis Pharmaceuticals, Inc.

Declaration of financial/other relationships

K.F., K.I., and B.P. have disclosed that they are employees of Milliman, Inc., a company that received funding from Novartis to conduct this study. C.P. and J.Z. have disclosed that they are employees of Novartis Pharmaceuticals, Inc.

CMRO peer reviewers may have received honoraria for their review work. The peer reviewers on this manuscript have disclosed that they have no relevant financial relationships.

Acknowledgement

No editorial assistance in the preparation of this article is to be declared.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 681.00 Add to cart

* Local tax will be added as applicable
 

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.